Interestingly, while DNMT3A R882 mutations were found to be enriched in AML (~50% of all DNMT3A mutations), they are decreased in frequency in CHIP (~10%) and other myeloid neoplasms including MDS (~25–30%). Here, STUB1 is linked to myelodysplastic syndrome.